OKYO Pharma Limited Sponsored ADR (OKYO) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
OKYO Pharma Limited announced the purchase of 80,000 ordinary shares by Panetta Partners Limited, an entity associated with its Executive Chairman Gabriele Cerrone, at $1.15 each, increasing his total ownership to 28.97%. The company, which is advancing innovative treatments for inflammatory dry eye disease and neuropathic corneal pain, has successfully completed a Phase 2 trial for its drug candidate OK-101 and is preparing for a Phase 2 trial to treat corneal neuropathic pain.
For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.
